INOVIQ's exosomes therapy to target breast cancer cells. Picture Getty
Health & Biotech
INOVIQ (ASX:IIQ) said it has created specialised exosomes (EEVs) designed to target and destroy breast cancer cells in a lab setting.
In the study, IIQ inserted a cancer targeting protein, chimeric antigen receptor (or CAR), into immune cells, which released the modified/engineered exosomes.
This protein acts like a homing device, guiding the exosomes to the breast cancer cells. Overall, the study found that these engineered exosomes were successful in finding and killing breast cancer cells in their experiments conducted in vitro.
The modified exosomes were isolated and concentrated using INOVIQ’s proprietary EXO-ACE technology, which recovered more than 80% of exosomes with over 95% purity.
In the tests, 75% of breast cancer cells treated with these exosomes experienced cell death within 72 hours.
Encouraged by these promising results, INOVIQ said it plans to further develop its exosome therapeutics program, initially focusing on using immune-cell derived exosomes to treat metastatic breast and ovarian cancers.
Additionally, exosomes can be engineered and loaded with drug cargo, such as RNA therapeutics, to target and deliver effective treatments for neurological diseases across the blood-brain barrier.
CEO Leearne Hinch said INOVIQ has established core capabilities in-house to engineer, load and produce exosomes for therapeutic applications.
“These data highlight the potential of immune-cell derived exosomes as an effective cancer therapy and the potential for RNA drug-loaded exosome therapeutics,” Hinch said.
The company is now moving forward with this program, as it aims to advance towards key preclinical in vitro and in vivo milestones for cancer starting in CY24.
“Preclinical in vivo data are expected to support discussions with pharmaceutical companies for potential partnered exosome therapeutic opportunities,” Hinch added.
INOVIQ’s share price was up +45% this morning.
Telix Pharmaceuticals (ASX:TLX) has completed the submission of a Biologics License Application (BLA) to the US FDA for its investigational radiodiagnostic PET agent, TLX250-CDx.
This application seeks to classify kidney masses as clear cell renal cell carcinoma (ccRCC), which is the predominant and aggressive form of kidney cancer.
The submission was based on the successful global Phase III ZIRCON study, which demonstrated high sensitivity and specificity for ccRCC detection.
Telix has also requested a Priority Review to expedite the FDA’s evaluation process. If approved, TLX250-CDx would be the first targeted radiopharmaceutical imaging agent specifically for kidney cancer commercially available in the US.
Telix has launched programs in different regions like the US, Europe, and Australia to give patients continued access to TLX250-CDx outside of clinical trials. These programs are for patients who don’t have other suitable treatment options available.
James Stonecypher, Telix’s chief development officer, says completing the BLA submission for TLX250-CDx brings its breakthrough kidney cancer imaging agent closer to being available in the market as a non-invasive diagnostic tool for patients.
“We believe TLX250-CDx is a natural follow-on product to Illuccix as it is targeted at the same clinical stakeholders, the urologist and urologic oncologist, and leverages the proven commercial and distribution infrastructure developed through the launch of Illuccix,” he said.
Telix’s share price was flat this morning.
Health & Biotech
Health & Biotech
Health & Biotech
